ストックスクリーナーアプリを入手
1.18
4.84%
-0.06
前日終値:
$1.24
開ける：
$1.25
24時間の取引高:
35,306
Relative Volume:
0.57
時価総額：
$19.67M
収益：
$3.20M
当期純損益:
$-10.90M
株価収益率:
-1.7513
EPS:
-0.6738
ネットキャッシュフロー:
$-7.92M
1週間 パフォーマンス:
-13.87%
1か月 パフォーマンス:
-4.07%
6か月 パフォーマンス:
-18.06%
1年 パフォーマンス:
+37.24%
1日の値動き範囲:
$1.18
$1.3099
1週間の範囲:
$1.18
$1.405
52週間の値動き範囲:
$0.83
$2.46
Marker Therapeutics Inc Stock (MRKR) Company Profile
名前
Marker Therapeutics Inc
セクター
電話
(713) 400-6400
住所
2450 HOLCOMBE BLVD, HOUSTON, TX
Compare MRKR vs VRTX, REGN, ARGX, MRNA, RVMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
MRKR
Marker Therapeutics Inc
|
1.18 | 20.34M | 3.20M | -10.90M | -7.92M | -0.6738 |
VRTX
Vertex Pharmaceuticals Inc
|
546.12 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
827.72 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,033.15 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
145.55 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
210.02 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
Marker Therapeutics Inc Stock (MRKR) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-03-05 | 開始されました | Canaccord Genuity | Buy |
| 2021-03-25 | 開始されました | Piper Sandler | Overweight |
| 2021-03-19 | 開始されました | Cantor Fitzgerald | Overweight |
| 2020-05-12 | ダウングレード | Piper Sandler | Overweight → Neutral |
| 2019-05-30 | 開始されました | ROTH Capital | Buy |
| 2019-03-01 | 開始されました | Janney | Buy |
| 2018-12-03 | アップグレード | Piper Jaffray | Neutral → Overweight |
すべてを表示
Marker Therapeutics Inc (MRKR) 最新ニュース
H.C. Wainwright reiterates Marker Therapeutics stock rating at buy By Investing.com - Investing.com India
US High Growth Tech Stocks To Watch In August 2026 - simplywall.st
Marker Therapeutics (MRKR) Rises 1.75%, Holding Above Key $1.10 SupportIchimoku Kumo Twist - vinanet.vn
Marker Therapeutics Stock Price Forecast. Should You Buy MRKR? - StockInvest.us
Marker Therapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
MRKR Advances 2.7% to $1.14 as Biotech Stock Holds Above Key SupportVanna Flow - Vinanet
Marker Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
CCORF Maintains Marker Therapeutics(MRKR.US) With Buy Rating, Maintains Target Price $8 - Moomoo
Stock List: Research Stocks from Around the World - GuruFocus
Marker Therapeutics Inc expected to post a loss of 22 cents a shareEarnings Preview - TradingView
Marker Therapeutics Inc (MRKR) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
MRKR Q1 2026 Earnings: Narrower-Than-Expected Loss of $0.16 Per Share Marks 14.44% EPS SurpriseProfit Inflection Point - vinanet.vn
MRKR Q1 2026 Earnings: Narrower Loss Beats Estimates as Investors Focus on Clinical MilestonesGuidance Downgrade Alert - vinanet.vn
Marker Therapeutics, Inc. Revenue Breakdown – NASDAQ:MRKR - TradingView
Marker Therapeutics Inc (MRKR) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Marker Therapeutics Inc (MRKR) Balance Sheet - TradingKey
Marker Therapeutics Inc (MRKR) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Marker Therapeutics Inc (MRKR) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Marker Therapeutics Inc (MRKR) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
TradingKey - TradingKey
MRKR|Marker Therapeutics Inc|Price:1.200|Chg%:-0.020 - TradingKey
MRKR|Marker Therapeutics Inc|Price:1.220|Chg%:-0.050 - TradingKey
Marker Therapeutics Inc (MRKR) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
US High Growth Tech Stocks to Watch for Potential Expansion - simplywall.st
High Growth Tech Stocks In The US Market - simplywall.st
Exploring High Growth Tech Stocks In The US For July 2026 - simplywall.st
MRKR Q1 2026 Earnings: Narrower Loss Beats Estimates as Pipeline Progress ContinuesGuidance Revision Trend - Vinanet
MRKR Q1 2026 Earnings: Narrower Loss Slightly Beats Expectations as Stock SlipsRevenue Warning Signal - vinanet.vn
Marker Therapeutics (MRKR) Slips 4.43% as Biotech Struggles, Holds Above $1.43 SupportBreakout Confirmation - dars.gov.et
Wainwright reiterates Buy on Marker Therapeutics stock, $10 target By Investing.com - Investing.com Canada
Wainwright reiterates Buy on Marker Therapeutics stock, $10 target - Investing.com
MSN Money - MSN
Marker Therapeutics, Inc.'s (NASDAQ:MRKR) Profit Outlook - simplywall.st
MRKR Q1 2026 Earnings: Narrower Loss Surpasses ExpectationsRevenue Growth Outlook - dars.gov.et
US High Growth Tech Stocks to Watch - simplywall.st
Marker Therapeutics Surges 11%: Key Levels and Potential Catalysts in FocusStandard Deviation - dars.gov.et
Exploring 3 High Growth Tech Stocks in the US Market - simplywall.st
Price to earnings forward of Marker Therapeutics, Inc. – NASDAQ:MRKR - TradingView
Marker Therapeutics Inc. (MRKR) Posts Modest Gain as Shares Approach Key ResistanceCash Flow Strong Stocks - dars.gov.et
Zacks Industry Outlook Indivior, Aurinia, Ironwood, Altimmune and Marker - The Globe and Mail
MRKR Forecast — Price Target — Prediction for 2027 - TradingView
Marker Therapeutics, Inc. Actuals & Estimates (NASDAQ:MRKR) - TradingView
Price to sales forward of Marker Therapeutics, Inc. – NASDAQ:MRKR - TradingView
Price to book forward of Marker Therapeutics, Inc. – NASDAQ:MRKR - TradingView
GX1 Forecast — Price Target — Prediction for 2027 - TradingView
SGMOQ Stock Price and Chart — OTC:SGMOQ - TradingView
Exploring High Growth Tech Stocks In The US Market June 2026 - simplywall.st
Marker Therapeutics Inc. Q1 2026 Earnings: Narrower-Than-Expected Loss Amid Pre-Revenue StatusMargin Improvement Report - dars.gov.et
Marker Therapeutics (MRKR) Slides 1.48% as Stock Hovers Near Key Support LevelValue Area Low - dars.gov.et
Marker Therapeutics Inc (MRKR) Institutional Confidence - TradingKey
Marker Therapeutics Inc (MRKR) Valuation: PE, PB & Fair Value Analysis - TradingKey
Marker Therapeutics Inc (MRKR) 財務データ
収益
当期純利益
現金流量
EPS
0.86%
0.31%
大文字化:
|
ボリューム (24 時間):